Epidemiological characteristics of 333 proven and probable invasive mould infections (IMIs) among solid organ transplant recipients (SOTRs) identified between 2004 and 2008 from the Prospective Antifungal Therapy Alliance (PATH) registry are presented. Liver transplant recipients (LTRs) had the lowest median time to IMIs (109 days; interquartile range [IQR] 24-611 days), the highest rate of disseminated disease (n/N = 18/33; 55%), and highest mortality (n/N = 21/33; 64%). Lung transplant recipients had highest median time to IMIs (486 days; IQR 117-1358 days) and lowest mortality (n/N = 31/184; 17%). Complete or partial response at week 12 in patients with invasive aspergillosis (IA) was 67% (n/N = 189/281), and 41% (n/N = 9/22) in mucormycosis patients. In the composite outcome of death or no response to therapy, LTRs had the worst outcome. Higher suspicion of mold infection and institution of appropriate antifungal prophylactic strategies are warranted, especially in high risk LTRs.
Introduction
Infections in immunocompromised hosts remain a moving target due to the introduction of potent immunosuppressive agents as well as the implementation of newer immunosuppressive protocols. Invasive fungal infections (IFIs) are particularly challenging, as they are associated with significant morbidity and mortality in SOTRs.
1,2 Among fungal infections, it is primarily IMIs that significantly contribute to mortality in SOTRs. The susceptibility of IFIs in general, and IMIs in particular, may differ among various types of SOTRs owing to the use of different induction regimens, post-operative immunosuppression levels, and anatomic characteristics of the patients. [1] [2] [3] Therefore, it is important to understand the characteristics of IMIs among various types of solid organ transplants (SOTs) to devise appropriate screening and prevention strategies. The small number of patients available for analysis mars validity of single-center retrospective studies. [4] [5] [6] Moreover, most of the single-center studies are of an earlier period and do not reflect current management practices. Large prospective multicenter studies are preferred for evaluating the epidemiological characteristics of IMIs among various types of SOTRs. Recently, two large studies, Transplant-Associated Infection Surveillance Network (TRANSNET) and PATH Alliance R registry, have attempted to define the epidemiological characteristics of IMIs among SOTRs. [7] [8] [9] However, a detailed description of IMIs in SOTs has not been provided. Herein we provide the comprehensive report of the unique epidemiological characteristics of IMIs from SOTRs from the PATH Alliance R registry.
Materials and methods
The PATH Alliance R registry is a sentinel surveillance network comprising 25 medical centers in the United States and Canada, which collected data on patients with IFIs between July 1, 2004, and September 30, 2008. The methodology for data collection has previously been described in detail. 10 Briefly, observed patient information was collected prospectively using a detailed electronic case report form for 12 weeks after diagnosis until the patients died or were lost to follow-up. All adult SOTRs >18 years of age, with proven and probable IFIs, as defined by European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group criteria, were identified, 11 We used the dissemination criteria as reported previously by Baddley JW 2010. 12 Disseminated IA was defined as extrapulmonary disease, excluding sinus disease. Cutaneous was deemed disseminated only if documented infection at nonconjoint site was noted. Isolation of mould from spinal fluid or CNS tissue was also considered disseminated. Patient data collected included demographics, underlying disease, prior antifungal therapy within 30 days before diagnosis, renal and hepatic function, presence of diabetes mellitus, requirement of mechanical ventilation, presence of intravenous central catheters, absolute neutrophil counts, receipt of total parenteral nutrition, prior treatment with corticosteroids or, other immunosuppressive agents (within 30 days before diagnosis), and concurrent viral or bacterial infections (within 30 and 7 days before diagnosis, respectively). Data pertaining to the IFIs included the fungal genus and species (when identified), diagnostic tests, sites of IFIs, antifungal therapy history, and therapeutic procedures. Histopathological specimens were identified at each institution via routine diagnostic methods.
Day of diagnosis (Day 1) was considered the day the first positive culture or pathology result was reported to the treating physician. Outcomes were reported 12 weeks after the diagnosis of IFI. Study design and patient enrollment was approved by the individual institutional/ethical review boards of the participating centers (listed in acknowledgments). All data were analyzed anonymously. Descriptive analyses were used for patient and pathogen data. Survival distribution functions were estimated using the KaplanMeier method, and compared using a log-rank test and multivariate Cox proportional hazards model. The following baseline factors were included in the multivariate model: serum creatinine level, disseminated infection status, dialysis status, concomitant bacterial infection, prior therapy for fungal infection, galactomannan assay result, dexamethasone or prednisone use, and cytomegalovirus status based on the reported literature. The data on monoclonal antibody (alemtuzumab) for induction were not available. Descriptive survival analyses were performed based on the whole patient group. Patients who were lost to follow-up prior to week 12 assessment were censored on the day of their last activity, as documented in the database.
Results

Epidemiology
A total of 333 cases of IMIs in SOTRs were noted in the PATH Alliance R registry. The majority, 63% (n/N = 209/333), were in lung transplant recipients followed by 14% (n/N = 45/333) in kidney transplant recipients, 10% (n/N = 33/333) in LTRs, 7% (n/N = 22/333) in heart transplant recipients, 6% (n/N = 20/333) in multiple-organ transplant recipients, and 1% (n/N = 4/333) in small bowel transplant recipients.
Concomitant bacterial infection was noted in at least one-third of the patients with IMIs, while concomitant cytomegalovirus infection (detected by PCR or p antigenemia) was noted in no more than 11% of IMI cases (Table 1) .
Tacrolimus and mycophenolate mofetil were the most commonly used maintenance immunosuppressive drugs (Table 2 ). In lung recipients 46% (n/N = 95/209) of patients used antifungal therapies 30 days prior to diagnosis (Table 2) .
IA was the most commonly diagnosed single IMI (74%; n/N = 246/333), followed by mucormycosis (4%; n/N = 13/333); LTRs had the highest rate of mucormycosis (21%; n/N = 7/33). Eleven percent (n/N = 38/333) of SOTRs had multiple mould infections. These infections were more frequently noted in lung and kidney transplant recipients at Organ function Creatinine (mg/dl), mean ± SD (range) 2.3 ± 1.4 (0.5-8.7) 2.0
Renal failure, n (%) the rate of 13% each. Aspergillus fumigatus was the most common species isolated irrespective of the type of organ transplants (Table A1 ). The median time to onset of IMIs among all SOTRs was 379 days (IQR 104-1215 days). The median time to onset of IMIs in LTRs (109 days; IQR 24-611 days) and heart transplant recipients (89 days; IQR 51-766 days) was shorter than the overall population, while kidney (406 days; IQR 149-1758 days), lung (486 days; IQR 117-1358 days), and small bowel (515.5 days; IQR 209-1629 days) transplant recipients experienced longer median times to onset of IMI (Figure 1) . Overall, time to onset of IMIs from the day of transplant was significantly different between the transplants groups (P < .01). Time to onset of IMIs in LTRs was significantly shorter than lung transplant recipients (P < .01) and kidney transplant recipients (P < .01).
Overall, 74% (n/N = 245/333) of SOTRs with IMIs had isolated pulmonary involvement followed by disseminated disease in 15% (n/N = 51/333). LTRs had the highest incidence of disseminated disease, noted in 55% (n/N = 18/33) of patients. Isolated sinus involvement appeared to be most common in kidney transplant recipients (11%; n/N = 5/45) ( Figure A1 ). Of the 24 reported cases of tracheobronchitis (19 tracheobronchial site only, five tracheobronchial and lung), 18 (75%) occurred in lung transplant recipients, three (13%) in kidney transplant recipients, one (4%) in LTRs, and two (8%) in multiple transplant recipients. The data on the categorization of fungal infections are presented in Table 3 . Of the 33 other moulds, two of 33 were Cladosporium, other specific molds include Chrysosporium, Exophiala, Exophiala spinifera, Exophiala jeanselmei, Ochroconis, Rhizopus, Scedosporium apiospermum, Trichophyton rubrum, Trichophyton rubrum, and Scopulariopsis brevicaulis. There was only one observed case for each organism. The other 21 moulds were unspeciated.
Outcomes
Overall mortality
Ninety-one percent (n/N = 302/333) of IMI patients completed 12 weeks of follow-up or were reported to have died. Overall mortality at 12 weeks was 25% (n/N = 76/302; Figure A2 ). LTRs had the highest mortality (64%; n/N = 21/33) at 12 weeks (P < .0001 versus all patients; Figure  A3 ), while lung transplant recipients had comparatively low mortality, 17% (n/N = 31/184). No differences in mortality were noted in regards to age, sex, or ethnicity. The higher mortality in LTRs remained statistically significant compared with overall SOTs (unadjusted log-rank test P < .0001; multivariate Cox model P < .001), even when the data were analyzed to compare survival in IA and mucormycosis separately (unadjusted log-rank test P < .0001; multivariate Cox model P < .01). At 12 weeks, LTR mortality was 61% (n/N = 14/23) for IA, 86% (n/N = 6/7) for mucormycosis, compared with 19% (26/137) for aspergillosis in lung transplant recipients The 12-week mortality in kidney and multiple transplants were 32% (9/25) and 35% (6/16), respectively. It is to be noted that all small bowel transplant recipients (n = 4) died at 12 weeks.
Overall response
The assessment of complete or partial response was available in 66% (n/N = 234/353) of patients (patients were counted for response to each unique pathogen reported). Complete or partial response was noted in 67% (n/N = 189/281) of patients with IA and 41% (n/N = 9/22) of patients with mucormycosis ( Figure A4 ). Age, sex, and ethnicity did not influence the response. In the composite outcome of response to therapy and all-cause mortality at 12 weeks, LTRs fared worst, with only 33% alive or with a response to therapy. Lung transplant recipients had the best outcome among SOT with 64% alive or with a response to therapy (Figure 2 ).
Discussion
The PATH Alliance R registry is one of three multicenter, epidemiological, surveillance databases that collected data between 2001 and 2008 on fungal infections in immunocompromised hosts. 8, 13 Our analyses extend the findings of previously reported analyses from the PATH Alliance R database by highlighting the unique characteristics of IMIs among various types of SOTRs. 7, 9 In this study, we identified higher risk of disseminated disease, higher mortality, and lack of response to antifungal therapy among LTRs, compared with other SOTRs, which has not been previously reported. IMIs were noted to occur earlier in the liver and heart transplant recipients, compared with lung or kidney transplant recipients, a finding that has been reported previously 7 . This observation is in contrast with an earlier multicenter study conducted 1998-2001, where LTRs were noted to have later onset of IA. 14 One of the interesting observations in this analysis was the evidence of disseminated mold infection at the time of presentation in LTRs. The exact reason for the higher propensity of disseminated disease in LTRs remains unclear but abnormalities in iron homeostasis have been proposed to play a role. 15 Indeed, as shown in another study, stainable iron in the hepatic explant was found to be independently associated with the early post-transplant fungal infections.
The relative magnitudes of Th1/Th2 imbalance, IL10, IL4, CXCL2, chemokine (C-C motif) ligand (CCL) 4, CCL3, IL1β and Toll-like receptors have not been specifically studied in LTRs. [17] [18] [19] It is plausible that these factors may selectively play a role in the dissemination of disease.
In a previously reported analysis of the PATH Alliance R registry, all-cause mortality at 12 weeks in patients with IA was only 22% among SOTRs. 9 However, a detailed analysis of mortality by organ group showed a higher mortality rate in IMIs in LTRs. Of these, 70% were due to IA. A higher propensity of disseminated disease at presentation may explain the excessive mortality and lack of response to antifungal therapy noted in LTRs as reported in other immunocompromised hosts. 20, 21 Limitations of the present study include differences in clinical practice patterns across the different centers, including selection bias, as investigators at centers may not have entered consecutive patients in the registry, and may have chosen to include those patients who were more sick. For example, this may lead to the collection of data for the sickest subset of LTRs. Moreover, the effect of center bias cannot be ignored as the number of patients recruited by the investigators at centers ranged from 21 to 809. 22 Other limitations include limited follow-up data as well as the lack of species identification in some of the isolates, and an inability to distinguish between prophylactic and empirical therapy. In addition, the absence of denominator data precluded calculating incidence rates and analyses of risk factors. This study could only compare between organ transplant groups and not between the infected and noninfected subsets of any particular organ transplant group. The use of galactomannan assay for the diagnosis was not very prevalent during the time data were collected, and the use of bronchoalveolar lavage for galactomannan tests may have improved the ability to establish diagnosis earlier. However, we would argue that LTRs are not routinely suspected to have IMIs, and by the time diagnosis is established disease may have already disseminated. Although Kaplan-Meier techniques were used to adjust for lost to follow-up cases, the overall survival rates may be affected by the 13% lost to followup cases. Despite these limitations, the data collected by the PATH Alliance R registry represent a large number of patients with SOTRs who develop IMIs.
In summary, identification of these previously unrecognized characteristics of IMIs in this study may put LTRs in a special category of mold infection in the current era, because when IMIs occur in LTRs, there may be a greater propensity for disseminated disease and higher mortality than other SOTRs. A large, prospective study assessing the specific risk factors associated with mold infections in SOTRs may be warranted to help design appropriate prophylactic strategies. 
